Journeys

COVID-19 UPDATES

COVID-19 continues to persist in the community at a relatively low level, mainly in the form of Omicron subvariants. Omicron subvariants are highly transmissible but

COVID-19 UPDATES

The latest in LAM research

Although the FDA’s approval of sirolimus for lymphangioleiomyomatosis was a major breakthrough in treating the disease, the drug does not work for all LAM patients.

The latest in LAM research
Menu